Eyenovia (NASDAQ:EYEN) Earns Neutral Rating from LADENBURG THALM/SH SH

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating restated by analysts at LADENBURG THALM/SH SH in a research note issued on Monday,Benzinga reports.

Other analysts have also issued research reports about the stock. HC Wainwright lowered shares of Eyenovia from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $12.00 to $2.00 in a research report on Monday. William Blair restated a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th. Finally, Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th.

Eyenovia Stock Performance

Shares of EYEN stock opened at $0.12 on Monday. The company’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.70. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.58. The firm has a market cap of $7.64 million, a PE ratio of -0.16 and a beta of 1.75. Eyenovia has a 12 month low of $0.09 and a 12 month high of $2.57.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period last year, the firm earned ($0.18) EPS. Equities research analysts expect that Eyenovia will post -0.5 EPS for the current fiscal year.

Insider Buying and Selling at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of Eyenovia stock in a transaction dated Monday, August 26th. The stock was bought at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares in the company, valued at $47,268.39. The trade was a 151.85 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Eyenovia

Institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eyenovia during the second quarter worth about $26,000. Ground Swell Capital LLC bought a new stake in Eyenovia during the second quarter worth about $27,000. Nations Financial Group Inc. IA ADV lifted its position in Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the period. Financial Management Network Inc. bought a new stake in Eyenovia during the third quarter worth about $39,000. Finally, SkyView Investment Advisors LLC bought a new stake in Eyenovia during the second quarter worth about $87,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.